文献速递浆细胞疾病

德国123例复发难治多发性骨髓瘤患者特立妥单抗真实世界分析

Real-world analysis of teclistamab in 123 RRMM patients from Germany.
PubMed 文献 · Leukemia · 2024-01-20

该回顾性研究评估了德国18个中心123例复发难治多发性骨髓瘤患者接受特立妥单抗治疗的疗效与耐受性,中位随访5.5个月,总缓解率59.3%,中位无进展生存期8.7个月,伴髓外病变、ISS 3分及ide-cel预处理患者缓解率与PFS较低,感染和≥3级血细胞减少最常见,真实世界疗效与关键试验相当。

要点

  • 123例RRMM患者中93%为三类难治、60%为五药难治,37%曾接受BCMA靶向预处理。
  • 总缓解率59.3%,中位无进展生存期8.7个月,中位随访5.5个月。
  • 髓外病变、ISS 3分及ide-cel预处理患者缓解率和PFS显著较低。

核心结论

  • 特立妥单抗在真实世界中的疗效和安全性特征与关键试验相当。

研究设计与样本

  • 回顾性评估德国18个中心123例接受特立妥单抗治疗的复发难治多发性骨髓瘤患者。

主要发现

  • 93%患者为三类难治,60%为五药难治,37%曾接受BCMA靶向预处理,其中21/123例(17.1%)曾接受ide-cel CAR-T细胞治疗。
  • 中位随访5.5个月,总缓解率59.3%,中位无进展生存期8.7个月。
  • 髓外病变患者总缓解率37%、中位PFS 2.1个月;ISS 3分患者总缓解率37%、中位PFS 1.3个月;ide-cel预处理患者总缓解率33%、中位PFS 1.8个月。
  • ide-cel预处理患者的缓解持续时间与抗BCMA初治患者相当。
  • 感染和≥3级血细胞减少是最常见的不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Teclistamab, a B-cell maturation antigen (BCMA) × CD3 directed bispecific antibody, has shown high response rates and durable remissions in the MAJESTEC-1 trial in patients with relapsed and refractory multiple myeloma (RRMM). We retrospectively assessed efficacy and tolerability in 123 patients treated at 18 different German centers to determine whether outcome is comparable in the real-world setting. Most patients had triple-class (93%) or penta-drug (60%) refractory disease, 37% of patients had received BCMA-directed pretreatment including idecabtagene vicleucel (ide-cel) CAR-T cell therapy (21/123, 17.1%). With a follow-up of 5.5 months, we observed an overall response rate (ORR) of 59.3% and a median progression-free survival (PFS) of 8.7 months. In subgroup analyses, we found significantly lower ORR and median PFS in patients with extramedullary disease (37%/2.1 months), and/or an ISS of 3 (37%/1.3 months), and ide-cel pretreated patients (33%/1.8 months). Nonetheless, the duration of response in ide-cel pretreated patients was comparable to that of anti-BCMA naive patients. Infections and grade ≥3 cytopenias were the most frequent adverse events. In summary, we found that teclistamab exhibited a comparable efficacy and safety profile in the real-world setting as in the pivotal trial.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Riedhammer C, Bassermann F, Besemer B, et al. Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia. 2024. PMID: 38245601. doi:10.1038/s41375-024-02154-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。